glp-1 masld Beyond glucagon-like peptide-1: The promise of polyagonists in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis—A systematic review of randomized trials Incretin-based therapies in MASLD/MASH: from

The phase 2 trial ran for 48 weeks total, and the weight loss curve had not fully plateaued by that point, suggesting continued benefits beyond the trial period

Retatrutide Half-Life and Steady State Understanding retatrutide's pharmacokinetics helps explain why the dosing schedule is structured as it is

Here are some others: Pancreatitis Pancreatitis is the inflammation or swelling of the pancreas and can, on rare occasions, potentially be triggered by GLP-1 drugs like Ozempic

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study